 SEATTLE, Nov. 11, 2021 GLOBE NEWSWIRE -- Icosavax, Inc. NASDAQ: ICVX, a biopharmaceutical company leveraging its innovative virus-like particle VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced that Adam Simpson, Chief Executive Officer of Icosavax, will participate in two upcoming investor conferences. 